Koo you wrote, "why do you refer to the trial as a phase 3 cardio trial. BETonMACE Clinical trial will be based on the endpoint of MACE"

Well, MACE is defined as major adverse cardiac events, or major adverse cardivascular events. This goes by many names. CETP Accelerate/Evactrapib trial describes it as "Time to First Occurence of the Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)." Reveal/Anacetrapib describes it as"risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events)"

We are doing a cardivascular trial. Our niche is that we are targeting the diabetic population.